Remarkably, ATO has shown the ability to induce immunogenic cell death in tumor cells while concurrently increasing the expression of PD-L1, a known immune checkpoint protein, through a mechanism dependent on mtDNA-STING signaling (Fig. 8). The gene discussed is STING1; the disease is neoplasm.